Cross-Sector entity
All 1 tracked stories fall under one category: fda-approval. Of the tracked stories, 1 of 1 also mention BPC-157, the most common co-covered peer. Each carries 3 original sources on average. We currently track 1 Cross-Sector story that mention Dr. Jessica Duncan, all published on August 3, 2026.
1 verified story tracked
Last mentioned: Aug 3, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: fda-approval. Of the tracked stories, 1 of 1 also mention BPC-157, the most common co-covered peer. Each carries 3 original sources on average. We currently track 1 Cross-Sector story that mention Dr. Jessica Duncan, all published on August 3, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Jessica Duncan. Shared-story counts are live from our verified record — not editorial picks.
FDA Advisory Panel Hearing
Marathon hearing votes 6-1 to back compounding of six peptide therapies, including BPC-157, TB-500, and MOTS-c, despite FDA scientists' concerns.
Despite FDA scientists’ safety concerns, an advisory panel overwhelmingly backed six peptide therapies for compounding, including TB-500 and MOTS-c. The biotech sector watches closely as the FDA prepares for rulemaking, which may redefine the boundary between pharmaceutical development and pharmacy compounding.
Source: wknofm.org · wmuk.org
